 This study will test the hypothesis that CF101, administered orally, will reduce intraocular pressure in patients with ocular hypertension andor glaucoma. Eligible patients with elevated intraocular pressure will be evaluated and treated by ophthalmologist investigators, and will receive either CF101 pills or placebo dummy pills twice daily for 16 weeks. Ocular pressure, visual fields, and other aspects of safety and effectiveness will be monitored on a regular basis. 